For physicians who care for patients with multiple sclerosis (MS), the use of disease-modifying therapies (DMTs) during the conception period and pregnancy raises important safety considerations. All DMTs have potential adverse effects on fertility, pregnancy outcomes, and breastfed infants. Although physicians are reluctant to prescribe DMTs to MS patients who are contemplating having a family or are already pregnant, treatment can be warranted in those who have active disease. This review assembles the most current information on the reproductive safety of approved and emerging DMTs drawn from the literature and information supplied by the manufacturers.
Introduction
Despite years of experience, there is limited information regarding the safety of approved disease-modifying therapies (DMTs) on fertility, pregnancy, and lactation in patients with multiple sclerosis (MS). Even less is known about the reproductive safety of DMTs in late-stage development.
Safety information concerning drug use in pregnancy relies heavily on the United States Food and Drug Administration (FDA) pregnancy categories (Table 1 ). Since 1979, experts have advocated for the need to revise the pregnancy categories, citing that drugs are often assigned a pregnancy category based on incomplete data and in some cases no data at all. 1, 2 
Parenteral DMTs of MS
Most data on the reproductive safety of parenteral DMTs are derived from case reports, prospective cohort studies, pregnancy registries, and safety databases maintained by manufacturers ( Table 2 ).
Interferon beta 1b and 1a
The interferon betas (IFNβs) are pregnancy category C drugs. 3 There is no evidence of infertility or teratogenicity with the IFNβs; however, exposure during the first trimester was reported to cause a dose-dependent abortive effect in monkeys. 3 Two recent reports examined outcomes in human fetuses exposed to IFNβ. The first was a longitudinal, controlled cohort study that identified an increased risk of fetal loss and low birth weight in 23 pregnancies among 16 women exposed to IFNβ in the first trimester. 4 The second, a retrospective review of 41 in utero pregnancies from eight clinical trials reported 20 healthy full-term infants, one healthy premature infant, nine induced abortions, eight spontaneous abortions, one fetal death, and a congenital anomaly (hydrocephalus). Although not statistically significant, the miscarriage rate in the IFNβ-exposed pregnancies was higher than the rate expected in the US population. 5 In contrast, information on IFNβ exposure during pregnancy from the IFNβ-1a global safety database and three IFNβ pregnancy registries found that the rates of spontaneous abortions and major congenital anomalies with IFNβ align with the expected rates in the general population [6] [7] [8] [9] ( Tables 3 and 4 ). While transfer of IFNβ across the placenta is not significant, it is unknown if IFNβ enters breast milk. 3 However, gastrointestinal absorption of intact proteins by breast-fed infants is unlikely. In the absence of any data, safe use of IFNβ while breastfeeding is undetermined. 3
Glatiramer acetate
Glatiramer acetate (GA), pregnancy category B, does not affect fertility or cause teratogenic complications. 3, 10 Knowledge of GA exposure in human pregnancy comes from a retrospective analysis of 215 pregnancies included in the manufacturer's safety database between 1996 and September 2002. There were five single cases of congenital abnormalities (finger anomaly, adrenal cyst, cardiomyopathy, urethrostenosis, anencephaly) and one birth defect (failure to thrive). The number of live births, miscarriages, and therapeutic terminations aligned with the general population 10 (Table 3) ; GA does not cross the placental barrier and is considered probably compatible with breastfeeding. 11 Given that GA is an amino acid polymer, it is unlikely to be absorbed intact across an infant's gastrointestinal mucosa.
Natalizumab
Natalizumab (pregnancy category C) is a humanized monoclonal IgG4 antibody that targets the α4-integrin receptor. 12 Animal studies evaluated the effects of natalizumab on fertility and pregnancy outcomes. In guinea pigs, reductions in pregnancy rates were observed at 30 mg/kg (36-fold the human clinical dose). No adverse effects on male fertility were reported. 13 Human uterine epithelium and embryonic tissue express α 4 -integrin receptors. Theoretically, natalizumab could interfere with implantation and embryonic development by inhibiting cell-cell interactions, but neither has been reported. 14 Cardiovascular complications are possible through inhibition of α 4 integrins involved in the development of the epicardium. However, in preclinical studies, no cardiac abnormalities were reported in monkeys treated with doses up to 30 mg/kg. 14 Information on pregnancy outcomes is limited. In the natalizumab MS and Crohn's disease clinical trial program, 41 pregnancies were reported. These pregnancies resulted in 12 full-term births, 10 ongoing pregnancies, six spontaneous abortions, and 13 with unknown outcomes, which align with expected outcomes in the US population. 15 In the gastroenterology literature, 102 pregnancies exposed to natalizumab were prospectively followed. There were 55 (53.4%) live births, no stillbirths, 27 (26.2%) elective terminations, 21 (20.4%) spontaneous abortions, and no congenital malformations. 16, 17 Interim results from the Tysabri Pregnancy Exposure Registry (TPER) were recently published ( Table 4 ). Fetal malformations were observed in 23 pregnancy outcomes in 21 women. Compared with historical controls, there were no significant differences in the rate of fetal malformations. 18 Natalizumab crosses the placenta in the second trimester and is secreted in human milk in small amounts. 12 Although it is unlikely that natalizumab would be absorbed intact across the gastrointestinal mucosa, safe use in nursing mothers is not established. 11, 12 Mitoxantrone Mitoxantrone (pregnancy category D) causes amennorhea. 3, 19 In animals, growth retardation and premature births were reported. 20 In mitoxantrone MS clinical trials, nine Table 1 . US FDA categories for use of medications in pregnancy.
FDA category Description
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus during the first trimester of pregnancy (and there is no evidence of risk in later trimesters). B
Animal reproduction studies have not demonstrated a fetal risk, but there are no adequate and well-controlled studies in pregnant women. Or Animal reproduction studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus during the first trimester of pregnancy (and there is no evidence of a risk in later trimesters). C Animal reproduction studies have shown an adverse effect on the fetus, there are no adequate and wellcontrolled studies in humans, and the benefits from the use of the drug in pregnant women may be acceptable despite its potential risks. Or There are no animal reproduction studies and no adequate and well-controlled studies in humans. D
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but the potential benefits from the use of the drug in pregnant women may be acceptable despite its potential risks. X Studies in animals or humans have demonstrated fetal abnormalities or there is positive evidence of fetal risk based on adverse reaction reports from investigational or marketing experience, or both, and the risk of the use of the drug in a pregnant woman clearly outweighs any possible benefit.
US FDA: United States Food and Drug Administration. pregnancies were reported resulting in six healthy infants, two pregnancies with unknown outcomes, and one ongoing pregnancy. 21 Patients should be instructed not to become pregnant while taking mitoxantrone and for at least six months after discontinuation. 11 Placental transfer of mitoxantrone is limited; however, it is secreted in milk and contraindicated when breastfeeding. 3, 22 Oral small molecules Two small molecules (fingolimod and teriflunomide) are approved for the treatment of relapsing forms of MS. Unlike proteins, small molecules have the potential to be absorbed by the digestive tract and widely distributed. Their potential for placental transmission is greater than for recombinant proteins (Table 5 ).
Fingolimod
Fingolimod (pregnancy category C) is an oral sphingosine 1-phosphate (S1P) receptor modulator that prevents the egress of lymphocytes from lymph nodes. 23 In rats, exposure to fingolimod caused a slight decrease in pregnancies; however, the effect of fingolimod on human fertility is unknown. [23] [24] [25] Fingolimod is teratogenic in rats. 23, 26 Congenital abnormalities, including persistent truncus arteriosus, were reported. 25, 26 This finding is not unexpected given that S1P receptors are involved in vascular development during embryogenesis. Limited information exists regarding the safety of fingolimod in pregnancy. In the fingolimod MS clinical trial program, 34 pregnancies resulted in 13 healthy infants, one infant with a tibia malformation believed to be unrelated to fingolimod, five spontaneous abortions, nine elective abortions, and six ongoing pregnancies. 27 A pregnancy registry is ongoing. When treatment is stopped, elimination of fingolimod takes approximately two months because of its long half-life. Patients should use effective contraception and wait at least two months following discontinuation before attempting conception. 23, 26 Fingolimod crosses the placenta and is secreted in breast milk; use in nursing mothers is not recommended. 23
Dimethyl fumarate
Fumaric acid esters (pregnancy category pending approval) have been used for the treatment of psoriasis for more than 50 years, primarily in Germany. 28 Despite a long history of use, there is little information on reproductive safety. Available studies on teratogenicity are conflicting. In preclinical studies conducted with Fumaderm ® (dimethyl fumarate and ethyl hydrogen fumarate), there was no evidence of teratogenicity. 29 In guinea pigs, exposure to fumaric acid 1% (about 400 mg/kg twice per day) did not cause adverse effects on reproduction or fetal growth. 30, 31 However, in rats, dimethyl fumarate at doses ≥ 178 mg/kg resulted in embryotoxicity and teratogenicity with malformations observed in organs, coccyx, and skull bone. 32 In an observational study of 15 psoriasis patients exposed to fumaric acid during pregnancy, there was one spontaneous abortion, one stillbirth, and no evidence of embryotoxicity or teratogenicity. 33 It is unknown if dimethyl fumarate crosses the placenta or is secreted in breast milk. Use of dimethyl fumarate during breastfeeding is not recommended. 28, 29 Teriflunomide Teriflunomide (pregnancy category X) is contraindicated in pregnant women and women of childbearing potential who are not using reliable contraception. 34 Teriflunomide causes teratogenicity throughout the period of organogenesis in rats and rabbits with high incidences of craniofacial, axial, and appendicular skeletal defects. Studies assessing the risk of male-mediated fetal toxicity have not been conducted; however, teriflunomide can be detected in human semen. Due to gastrointestinal reabsorption, following discontinu-ation the plasma concentration of teriflunomide can take eight months or longer (up to two years) to drop below 0.02 mg/l, a level considered safe for reproduction. If a patient, or a potential father, on teriflunomide wants to conceive or becomes pregnant, the drug should be stopped and an accelerated elimination procedure initiated. Cholestyramine 8 g every eight hours for 11 days is administered. If cholestyramine 8 g three times a day is not well tolerated, the dose can be decreased by 50%. 34 Early experience with teriflunomide in pregnant MS patients comes from the Teriflunomide Multiple Sclerosis Oral (TEMSO) study and the Teriflunomide Pharmacovigilance Database. In the TEMSO study, 11 pregnancies were reported resulting in six terminated pregnancies (all in women receiving teriflunomide), four miscarriages (one in the placebo group and three in the teriflunomide group), and one healthy newborn by a patient who was treated with teriflunomide for 31 days of her pregnancy. 35 The Teriflunomide Pharmacovigilance Database is a retrospective collection of pregnancy outcome data from 53 pregnant MS patients with direct (n=41) or indirect exposure (n=12) to teriflunomide. The 53 pregnancies resulted in 17 healthy newborns, 19 terminated pregnancies, nine miscarriages, and eight ongoing pregnancies. Eight of the 10 women with direct exposure to teriflunomide who delivered healthy newborns underwent the recommended drug elimination protocol in the first trimester. No structural or functional defects were reported. 36 Teriflunomide crosses the placenta and is detected in rat milk following a single oral dose. It is unknown if teriflunomide is secreted in human milk. 34 Until further information is available, breastfeeding is not recommended.
Laquinimod
Laquinimod (pregnancy category pending approval), a second-generation quinoline-3-carboxamide analog structurally related to roquinimex, is under investigation for relapsing forms of MS. 37, 38 Animal studies demonstrated fetal malformation in rats, but not in rabbits, exposed to roquinimex and other quinoline compounds. 37, 39 A theoretical concern with quinoline-3-carboxamides is their potential anti-angiogenic effect. 38 However, no case of fetal vascular malformations due to quinoline-3 carboxamide exposure has been reported. Until reproductive safety data are available, women of childbearing potential are advised to use effective contraception and lactating mothers should not breastfeed. 40
Cladribine
Parenteral cladribine (pregnancy category D) is indicated for the treatment of hairy cell leukemia and lymphoma. 41, 42 Recently, the development of oral cladribine for the treatment of MS was discontinued. Cladribine causes suppression of rapidly dividing cells, including testicular cells.
Men are advised to not father children while taking cladribine and for at least six months after its discontinuation. 41, 42 In animals, cladribine is teratogenic at all stages of utero development, but there is no evidence of teratogenicity in humans. [41] [42] [43] Data on cladribine exposure in human pregnancy are limited. 43, 44 A successful pregnancy following administration of cladribine to a patient with hairy cell leukemia was reported. 45 It is not known if cladribine crosses the placenta or is secreted in breast milk. However, given its molecular weight (~286), there is the possibility that cladribine crosses the placenta and is secreted in milk. 11, 41 Cladribine use while breastfeeding is not recommended. 11
Monoclonal antibodies
Several IgG1 monoclonal antibodies (mAbs) show promise in MS treatment. (Table 6 ). IgG1 antibodies do not cross the placenta in the first trimester, protecting the infant from exposure during the crucial period of organogenesis, from 18 to 50 days after conception. 46 However, they efficiently cross the placenta in the third trimester and could have immunological effects on the fetus.
Alemtuzumab
Alemtuzumab (pregnancy C) is a humanized IgG1 monoclonal anti-CD52 antibody that is FDA approved for B-cell chronic lymphocytic leukemia (B-CLL) and in late-stage development for relapsing MS. 47 No fertility complications have been reported; however, alemtuzumab may cause reversible infertility in males because of inactivation of mature sperm. 48 Since B-CLL affects mainly elderly patients, alemtuzumab reproductive toxicity studies have not been conducted. Alemtuzumab crosses the placenta (second and third trimesters) and enters breast milk. Breastfeeding should be avoided for at least three months after stopping treatment. 43, 49 
Anti-CD20 monoclonal antibodies
Rituximab is no longer being evaluated for the treatment of MS; however, two second-generation anti-CD20 mAbs are in phase 3 trials: ocrelizumab and ofatumumab. Rituximab (pregnancy category C), a chimeric IgG1 anti-CD20 mAb, is FDA approved for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other select autoimmune diseases. 50 Experience with rituximab may provide some guidance on the reproductive safety of second-generation anti-CD20 mAbs. In animal studies, infertility and congenital malformations were not observed; however, a dose-dependent depletion of B-cells was observed in fetuses. 50, 51 Case reports of rituximab treatment during pregnancy suggest that it does not result in serious effects on newborns. 52 However, women are instructed to avoid pregnancy while taking rituximab. Due to its long half-life, it was proposed that treatment be stopped 12 months before conception (although this proposal may be overly conservative). 52 Rituximab likely crosses the placental barrier and is secreted in milk in small amounts; breastfeeding is not recommended. 50, 53 Ocrelizumab (pregnancy category pending approval) is a humanized IgG1 CD20 mAb in clinical trials for relapsing and progressive forms of MS. To date, no information has been published on its reproductive safety. Ofatumumab (pregnancy category C), a human IgG1 anti-CD20 mAb, is FDA approved for refractory chronic lymphocytic leukemia and is being investigated in MS. Fertility studies with ofatumumab have not been conducted. In monkeys, fetal malformations were not observed with 100 mg/kg ofatumumab, the highest dose tested. 54, 55 The same instructions for rituximab use in women of childbearing potential apply to ofatumumab and ocrelizumab.
Daclizumab
Daclizumab (pregnancy category C), a humanized IgG1 monoclonal anti-CD25 antibody, was FDA approved in 1997 for the prevention of renal allograft rejection and is being investigated for the treatment of MS. Fertility studies have not been conducted with daclizumab. 56 Fetal malformations were not observed with daclizumab in monkeys, although there was an increase in prenatal loss. Women of childbearing potential are advised to use effective contraception while taking daclizumab and for four months after discontinuation. 56 Very low concentrations of daclizumab are secreted in breast milk of lactating monkeys. Breastfeeding is not recommended during treatment. 57
Summary
Unfortunately, no DMT is proven to be safe during pregnancy or while breastfeeding. Despite limited data on their reproductive risks, small molecules are considered to carry unacceptable risks due to their potential to cross the pla-centa and be secreted in breast milk. Risks for some small molecules are considered established (mitoxantrone, teriflunomide, and cladribine) whereas others remain suspected (fingolimod, dimethyl fumarate, and laquinimod). In contrast monoclonal antibodies do not cross the placenta during organogenesis and therefore are unlikely to be teratogenic; however, they can cross the placenta during the second and third trimesters, and use of these drugs late in pregnancy could have immunological consequences for the unborn infant. Although monoclonal antibodies could be secreted in breast milk, because they are proteins that require parenteral administration, it is unlikely that they will be absorbed intact by breastfed infants. Similar reasoning applies to the IFNs; however, ongoing use of IFNs in women planning pregnancy may be relatively contra-indicated because of their possible abortifacient property. In women who need to continue DMTs, GA appears to be the only available treatment that can be used with relative safety. While treatment with GA can be continued during pregnancy, there is always the risk of unforeseen adverse events. It is hoped that this review will be a useful source for clinicians who are faced with the challenge of counseling their patients about the potential risks and benefits of continuing with, or abstaining from, treatment before, during, and after pregnancy.
